PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Cadilha, B.L.* ; Benmebarek, M.R.* ; Dorman, K.* ; Oner, A.* ; Lorenzini, T.* ; Obeck, H.* ; Vänttinen, M.* ; Pilato, M.D.* ; Pruessmann, J.N.* ; Stoiber, S.* ; Huynh, D.* ; Märkl, F.* ; Seifert, M.* ; Manske, K.* ; Suarez-Gosalvez, J.* ; Zeng, Y.* ; Lesch, S.* ; Karches, C.H.* ; Heise, C.* ; Gottschlich, A.* ; Thomas, M. ; Marr, C. ; Zhang, J.* ; Pandey, D.* ; Feuchtinger, T.* ; Subklewe, M.* ; Mempel, T.R.* ; Endres, S.* ; Kobold, S.

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.

Sci. Adv. 7:eabi5781 (2021)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response via inhibitory factors such as transforming growth factor–β (TGF-β). Treg cells expressing the C-C chemokine receptor 8 (CCR8) have been associated with poor prognosis in solid tumors. We postulated that CCR8 could be exploited to redirect effector T cells to the tumor site while a dominant-negative TGF-β receptor 2 (DNR) can simultaneously shield them from TGF-β. We identified that CCL1 from activated T cells potentiates a feedback loop for CCR8+ T cell recruitment to the tumor site. This sustained and improved infiltration of engineered T cells synergized with TGF-β shielding for improved therapeutic efficacy. Our results demonstrate that addition of CCR8 and DNR into CAR T cells can render them effective in solid tumors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
14.136
3.445
7
28
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Growth-factor-beta; Receptor; Driven
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 2375-2548
e-ISSN 2375-2548
Journal Science Advances
Quellenangaben Volume: 7, Issue: 24, Pages: , Article Number: eabi5781 Supplement: ,
Publisher American Association for the Advancement of Science (AAAS)
Publishing Place Washington, DC [u.a.]
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
Institute of Computational Biology (ICB)
POF-Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
Research field(s) Immune Response and Infection
Enabling and Novel Technologies
PSP Element(s) G-522100-001
G-503800-001
Grants Ernst-Jung-Stiftung
Melanoma Research Alliance Grants
Marie-Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Marie-Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector foundation
Else Kroner-Fresenius-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung Project Oncoattract
European Research Council
German Research Foundation (DFG)
NIH
Fritz-Bender Foundation
European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program
Volkswagen Foundation (project OntoTime)
Jose-Carreras Foundation
Deutsche Gesellschaft fur Immun-und Targeted-therapie
German Cancer Aid
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
DOI 10.1126/sciadv.abi5781
WOS ID WOS:000659923500013
Scopus ID 85107474573
PubMed ID 34108220
Erfassungsdatum 2021-07-06
[➜Report correction]